2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- manufacturers
|
| 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- Basic information |
Product Name: | 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- | Synonyms: | 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)-;Complement factor D-IN-2;JYN42346;Complement System,complement,diseases,inhibit,factor,Complement factor D IN 2,autoimmune,Inhibitor,Complement factor DIN2;(1R,3S,5R)-2-{2-[3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl]acetyl}-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide | CAS: | 1903742-34-6 | MF: | C27H24BrN7O3 | MW: | 574.43 | EINECS: | | Product Categories: | | Mol File: | 1903742-34-6.mol | |
| 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- Chemical Properties |
Boiling point | 849.1±65.0 °C(Predicted) | density | 1.67±0.1 g/cm3(Predicted) | pka | 11.72±0.20(Predicted) | form | Solid | color | White to off-white |
| 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- Usage And Synthesis |
Biological Activity | Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases[1].
Complement factor D-IN-2 reduces the excessive activation of complement factor D[1]. | References | [1]. GADHACHANDA VR, et, al. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders. WO2015130838A1. |
| 2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-, (1R,3S,5R)- Preparation Products And Raw materials |
|